Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
Background We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a...
Enregistré dans:
Auteurs principaux: | Feroz Ahmad, Robert D. Mitchell, Tom Houben, Angela Palo, Tulasi Yadati, Andrew J. Parnell, Ketan Patel, Ronit Shiri‐Sverdlov, David S. Leake |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fda9f1c4cdf04659bffbd7796e762592 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The Potential Role of Electronegative High-Density Lipoprotein H5 Subfraction in RA-Related Atherosclerosis
par: Ching-Kun Chang, et autres
Publié: (2021) -
Monocyte/High-Density Lipoprotein Ratio Predicts the Prognosis of Large Artery Atherosclerosis Ischemic Stroke
par: Youyu Li, et autres
Publié: (2021) -
The Association of Syntax Score with Levels of Lipoprotein(a) and Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease and Different Low-Density Lipoprotein Cholesterol Levels
par: Xu W, et autres
Publié: (2020) -
Detection of Low Density Lipoprotein—Comparison of Electrochemical Immuno- and Aptasensor
par: Daria Rudewicz-Kowalczyk, et autres
Publié: (2021) -
Efecto inmunosupresor in vitro de las lipoproteínas de baja densidad
par: González R,Margarita, et autres
Publié: (1999)